Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: H05AA04

Eladynos(abaloparatide)

Osteoporosis, Postmenopausal;Osteoporosis

Marketing Authorisation Holder: Theramex Ireland Limited

EMA Authorisation: 12/12/2022

INN: abaloparatide

Indication

Treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Eladynos — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.